Psychiatric Genomics Consortium [PGC-SZ], 2014) . Often such studies, in addition to probands with BD and SZ, include a group which meets criteria for schizoaffective disorder (SAD). Traditional family studies have shown evidence of familial overlap between SAD and both SZ and BD, which has been confirmed by Scandinavian population registered-based studies (Cardno & Owen, 2014) . Depending on the proportion of cases diagnosed as SAD, the inclusion of these individuals may impact on the genetic findings when considering the relationship between SZ and BD (Cardno & Owen, 2014) .
The concept and diagnostic criteria for SAD have been controversial with DSM-IV-TR noting that the SAD category "fills a necessary and important hole in the diagnostic system, but unfortunately it does not do its job very well." The approaches taken by the various classification systems have differed, with Research Diagnostic Criteria (RDC) for SAD bipolar type broader than those proposed by the World Health Organization and the American Psychiatric Association (APA) (Spitzer, Endicott, & Robins, 1978) . RDC does not require psychotic symptoms in the absence of a mood episode and rather gives a list of specific psychotic symptoms "suggesting schizophrenia" occurring in a manic episode that would point to a diagnosis of SABP. These differences result in more patients being diagnosed in the schizoaffective categories under RDC compared to the ICD and DSM systems. ) and hence "may be of particular use to for identifying common susceptibility loci GWAS" (Hamshere et al., 2009 ). In addition, variation at genes encoding GABA A -receptor subunits were associated with risk of RDC-SABP and this association was relatively specific to this diagnostic subset, with no association to SZ or BD (Craddock et al., 2010) . This finding was replicated in an independent study (Breuer et al., 2011) .
Finally, polygenic score analysis of RDC-SABP using SZ-derived polygenic scores showed that the polygenic influences on SZ had a greater overlap with SABP than those for the remaining BD individuals .
Aiming to identify loci that are associated with RDC-SABP at statistically stringent levels of significance (p < 5 × 10 −8 ), we have genotyped a replication sample using the Illumina Infinium HD genotyping array, the ImmunoChip, focusing on the 10 SNPs that reached a p-value threshold of <10 −5 in the WTCCC study (Hamshere et al., 2009) , and combined the two datasets by meta-analysis (total RDC-SABP cases, n = 423 and controls, n = 9,494).
| MATERIALS AND METHODS

| Samples
All participants were unrelated, white European, living in the British
Isles. The protocols and procedures were approved by the relevant ethics review panels where patients were recruited.
| Original WTCCC sample set
The WTCCC bipolar disorder sample and dataset has been previously reported, and as such the sample and collection information are not included (WTCCC, 2007) . Analyses of subsets of these BD samples, including those individuals rated as RDC-SABP, have also been reported (n = 279) (Craddock et al., 2010; Green et al., 2010; Hamshere et al., 2009) . RDC is a broader definition of SABP, and provide more delineation between individuals on the basis of the pattern of mood psychotic symptomatology than rating by DSM-IV (APA, 1994; Hamshere et al., 2011) . Inter-rater reliability was formally assessed using 20 random cases. Mean kappa statistics were 0.86 for RDC.
| Replication sample set
The independent replication RDC-SABP (n = 144) sample set was part of the bipolar disorder sample, the BDRN sample (n = 1,849). A description of this BD collection has been detailed in Green et al. (2013 Green et al. ( , 2016 . WTCCC2 set was used as the control sample (n = 6,599), and the characteristics and recruitment of which have been described in WTCCC (2007). These controls are not screened to exclude the presence of psychiatric illness.
| Genotyping
The genotyping was performed using the custom Illumina Infinium HD genotyping array, the ImmunoChip. The ImmunoChip BD genotyping study has been previously reported for the 1,218 BD cases and 2,913 controls (Green et al., 2013) but not for the subset of RDC SABP cases.
Additional samples were genotyped at University College London (UCL) to increase the sample size, including 631 BD cases (44 RDC-SABP cases) and 3,646 WTCCC2 controls. In total, the replication RDC-SABP sample consists of 144 RDC-SABP cases and 6,556 WTCCC2 controls, which are independent of the original WTCCC GWAS.
This study focuses on 10 SNPs that were included on the ImmunoChip as part of the "investigator-specific SNP selection for replication" and were independently associated SNPs (r 2 < 0.2) with an association signal of p < 10 −5 for RDC-SABP cases against controls in our previous study Hamshere et al. (2009) . It is worth noting that in this study, the Cochran-Armitage trend test of genotype distributions with disease was employed, whereas the data presented here were analyzed using logistic regression of disease state with a genomic inflation factor (λ) of 1.06. As such the p-values and ORs stated may differ slightly from the original publication and the p-values for two SNPs are slightly >10
−5
. We note that following Principal Component Analysis (PCA) (data shown in supplementary methods), SNP rs2352974 remains genome-wide significant when combined with the replication dataset by meta-analysis.
| Statistical analysis
A brief summary of the methodology is described here and more detailed description is available in the Supplementary Materials. The BDRN sample set was genotyped on the ImmunoChip at either the Sanger Institute or UCL sequencing facility. The bipolar disorder dataset genotyped at the Sanger Institute has been published (Green et al., 2013 ) and this genotype calling and quality control pipeline was implemented for the sample genotyped at UCL. Briefly, the genotypes were called by GenoSNP software (Giannoulatou, Yau, Colella, Ragoussis, & Holmes, 2008) . The data management and quality control assessment was performed using PLINK (v1.07) (Purcell et al., 2007 ) and a series of shell scripts initially for all BD and control samples.
We planned to combine the data genotyped at the two centers. In order to highlight any potential "batch effects" problems that might prevent the combining of the data, we included nine identical samples from the first center to be genotyped by UCL. The concordance rate for the nine samples across overlapping SNPs (n = 96,184) was very high reaching 99.997%. Thus, we felt confident in combining the datasets.
From the total BD dataset, 144 RDC-SABP and controls were extracted (n = 6,556) and quality control analysis performed. PCA was performed with Eigenstrat on the combined sample and any individual outliers that did not cluster near to the HapMap European individuals were removed in order to maximize the ethnic homogeneity of our sample Price et al., 2006) . The genomic inflation factor was calculated using 43 K SNPs in relative linkage (α = 1).
| Meta-analysis
The RDC-SABP replication dataset was combined with the original RDC-SABP (WTCCC, 2007) dataset by fixed-effects meta-analysis using PLINK (v1.07) (Purcell et al., 2007) to estimate a common odds ratio weighted by individual study standard errors (SE).
| RESULTS
An independent replication sample of 144 cases (RDC-SABP) and 6,559 controls SNPs was genotyped on the ImmunoChip Illumina array. We have focused on 10 SNPs that showed an independent association (r 2 < 0.2) signal at p < 10 −5 for RDC-SABP against controls in our previous study of the WTCCC dataset previously (Hamshere et al., 2009) . We combined our replication data with the WTCCC SNP data by fixed effect meta-analysis. SNP, rs2352974, on chromosome 3p21.31 met genome-wide association (p = 4.37 × 10
, OR = 0.67).
This SNP resides within the intronic region of the gene, TRAIP (TRAF interacting protein).
A meta-analysis of all SNPs on the ImmunoChip was also performed (data not presented). No additional individual SNP was associated at levels that exceed the accepted genome-wide levels of significance (p < 5 × 10 −8 ; Table 1 ).
| DISCUSSION
Combining an independent sample with our previous dataset ( There is much debate around the clinical usefulness and the nosological status of diagnostic category SAD. Discussions include whether SAD is a form of schizophrenia, affective disorder, a combination of the two, or should be regarded as a separate disease entity (Craddock, O'Donovan, & Owen, 2009) . To add to this, there are concerns over the poor reliability of diagnosis (Maj, Pirozzi, Formicola, Bartoli, & Bucci, 2000; Santelmann, Franklin, Bußhoff, & Baethge, 2015) and apparent low diagnostic stability over time (Laursen et al., 2005; Schwartz et al., 2000) . Our findings here, of a susceptibility locus specific (i.e., not identified in BD or SZ datasets) for RDC-SABP, combined with our previous genetic findings for SABP do further support the notion that SABP is a partly independent diagnostic category, with some specific biological characteristics not shared with other phenotypes (Craddock et al., , 2010 Hamshere et al., 2009 ).
Larger well phenotypically defined samples, although challenging to collect, we envisage will enable the identification of additional risk loci that are specific to SABP, and loci that also confer risk to both or either BD and/or SZ.
In summary, within our UK RDC-SABP sample, we have identified a genome-wide significantly associated locus at an intronic SNP in TRAIP. Our findings further indicate the importance of research examining clinical diagnostic phenotypes, which in turn will be ultimately important for clinical practice.
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